ADMA ADMA Biologics, Inc. - Fundamental Analysis
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Stock trades at a substantial premium to Graham Number and intrinsic value, indicating valuation is driven by growth expectations rather than conservative fundamentals.
- High profit margins and ROE suggest strong business model
- Low debt/equity ratio supports financial stability
- P/E of 18.72 is high relative to Graham Number ($5.92)
- Price/Sales of 7.86 is elevated for a biotech with no dividend
- Intrinsic value ($6.02) is significantly below current price ($16.10)
Growth is evident in revenue but not yet translating into earnings growth, raising questions about scalability and margin sustainability.
- 12.00% YoY revenue growth indicates top-line momentum
- Recent quarters show strong EPS surprises (e.g., +62.5%)
- Zero earnings growth (YoY) despite revenue growth
- No forward PEG ratio available, limiting growth valuation clarity
- Q/Q earnings growth of 1.40% is modest
Historical earnings performance shows volatility and inconsistency, with a recent decline in surprise accuracy despite prior strong beats.
- Consistent earnings beat in several quarters (e.g., Q2 2024: +62.5%)
- Improving EPS trend from deep losses to positive profitability
- Recent quarters show mixed results (e.g., -33.3% surprise in Q1 2025)
- Average earnings surprise over last 4 quarters is -12.96%
Despite strong balance sheet, the Piotroski F-Score of 3/9 signals underlying financial weaknesses, including potential issues with operating cash flow or asset turnover.
- Low debt/equity (0.19) and high current ratio (7.13)
- No Altman Z-Score available, but low leverage suggests low bankruptcy risk
- Piotroski F-Score of 3/9 indicates weak financial health
- Low score suggests poor capital efficiency, declining ROA, or negative cash flow trends
No dividend policy exists, which is typical for growth biotechs but limits income appeal.
- No dividend yield or payout ratio
- Dividend Strength: 0/100
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ADMA and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ADMA
ADMA Biologics, Inc.
Primary
|
+528.9% | +356.1% | +0.1% | -9.6% | -7.3% | +0.1% |
|
ACLX
Arcellx, Inc.
Peer
|
+281.6% | +132.1% | -2.3% | -10.1% | -6.9% | -6.4% |
|
BLLN
BillionToOne, Inc.
Peer
|
-19.6% | -19.6% | -19.6% | -19.6% | +1.4% | -1.3% |
|
ACAD
ACADIA Pharmaceuticals Inc.
Peer
|
-52.2% | +28.8% | +18.2% | -6.8% | -10.3% | +8.9% |
|
AMRX
Amneal Pharmaceuticals, Inc.
Peer
|
+176.1% | +531.6% | +52.0% | +66.1% | +4.0% | -0.1% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ADMA
ADMA Biologics, Inc.
|
NEUTRAL | $3.84B | 18.72 | 63.2% | 42.9% | $16.1 | |
|
ACLX
Arcellx, Inc.
|
BEARISH | $3.71B | - | -47.2% | -% | $64.11 | |
|
BLLN
BillionToOne, Inc.
|
NEUTRAL | $4.01B | - | -% | -4.4% | $87.57 | |
|
ACAD
ACADIA Pharmaceuticals Inc.
|
BULLISH | $4.06B | 15.48 | 35.0% | 24.9% | $23.99 | |
|
AMRX
Amneal Pharmaceuticals, Inc.
|
NEUTRAL | $4.21B | 1339.0 | -% | 0.2% | $13.39 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-17 | GROSSMAN ADAM S | Chief Executive Officer | Sale | 21,000 | $337,680 |
| 2026-02-17 | GROSSMAN ADAM S | Chief Executive Officer | Option Exercise | 15,000 | $81,000 |
| 2026-02-09 | ELMS STEVEN A | Director | Stock Award | 10,690 | - |
| 2026-02-09 | SALAS EDUARDO RENE | Director | Stock Award | 10,690 | - |
| 2026-02-09 | KESTENBERG-MESSINA KAITLIN M. | Officer | Stock Award | 91,631 | - |
| 2026-02-09 | GROSSMAN JERROLD B | Director | Stock Award | 10,690 | - |
| 2026-02-09 | GROSSMAN ADAM S | Chief Executive Officer | Stock Award | 282,529 | - |
| 2026-02-09 | GUIHEEN LAWRENCE P | Director | Stock Award | 10,690 | - |
| 2026-02-09 | FINGER ALISON CECILY | Director | Stock Award | 10,690 | - |
| 2026-02-09 | KWON YOUNG T. PH.D. | Director | Stock Award | 10,690 | - |
| 2025-12-15 | GROSSMAN ADAM S | Chief Executive Officer | Sale | 21,000 | $415,590 |
| 2025-12-15 | GROSSMAN ADAM S | Chief Executive Officer | Option Exercise | 15,000 | $81,000 |
| 2025-11-19 | GROSSMAN ADAM S | Chief Executive Officer | Sale | 21,000 | $336,000 |
| 2025-11-19 | GROSSMAN ADAM S | Chief Executive Officer | Option Exercise | 15,000 | $81,000 |
| 2025-10-24 | GROSSMAN ADAM S | Chief Executive Officer | Sale | 21,000 | $336,000 |
Past News Coverage
Recent headlines mentioning ADMA from our newsroom.